Altimmune Stock Profit Margin

ALT Stock  USD 5.64  0.28  4.73%   
Altimmune fundamentals help investors to digest information that contributes to Altimmune's financial success or failures. It also enables traders to predict the movement of Altimmune Stock. The fundamental analysis module provides a way to measure Altimmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Altimmune stock.
Last ReportedProjected for Next Year
Net Loss-4.8 K-4.5 K
Pretax Profit Margin is likely to drop to -4,991 in 2025. Operating Profit Margin is likely to gain to -4,901 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Altimmune Company Profit Margin Analysis

Altimmune's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Current Altimmune Profit Margin

    
  (4.5K)  
Most of Altimmune's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Altimmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Altimmune Profit Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Altimmune is extremely important. It helps to project a fair market value of Altimmune Stock properly, considering its historical fundamentals such as Profit Margin. Since Altimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Altimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Altimmune's interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Altimmune Pretax Profit Margin

Pretax Profit Margin

(4,990.6)

At this time, Altimmune's Pretax Profit Margin is comparatively stable compared to the past year.

Altimmune Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Altimmune's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics of similar companies.
Altimmune is currently under evaluation in profit margin category among its peers.

Altimmune Current Valuation Drivers

We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap289.2M378.2M771.9M599.0M511.9M537.5M
Enterprise Value175.1M189.4M662.0M464.6M476.7M500.5M

Altimmune ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Altimmune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Altimmune's managers, analysts, and investors.
Environmental
Governance
Social

Fund Asset Allocation for Altimmune

The fund invests 21.57% of asset under management in tradable equity instruments, with the rest of investments concentrated in bonds (15.26%) and various exotic instruments.
Asset allocation divides Altimmune's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.

Altimmune Fundamentals

About Altimmune Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.